CD8A and neoplasm: The PARP inhibitor olaparib induces CD8+ T cell infiltration and activation by inducing the cGAS/STING-dependent pro-inflammatory cytokine production in tumor cells, providing a rationale for combining PARP inhibition with immunotherapies for the treatment of TNBC [193].